Business Daily Media

Business Marketing

.

ReShape Lifesciences Announces Distribution in Australia

  • Written by ACN Newswire
image
SAN CLEMENTE, CA & MELBOURNE, AU, Apr 18, 2019 - (ACN Newswire) - ReShape Lifesciences™, a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announces that as of April 1, 2019, the company was selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market.

The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND while it was owned by Allergan and Apollo Endosurgery respectively. Concurrent with this relationship, ReShape Lifesciences has fully taken over all distribution of the LAP-BAND product in Australia from Apollo Endosurgery, Inc. and will subsequently be recognizing revenue from sales of the product in Australia.

Over 120,000 LAP-BAND procedures have taken place in Australia since the product was launched in the country, making Australia one of the largest worldwide markets for LAP-BAND outside of the U.S. Australia was one of the early adopters of the LAP-BAND technology and has produced some of the strongest data and research on the product. According to the OECD 2017 Obesity Update, based on self-reported data, 27.9% of the Australian adult population are obese, the fifth highest obesity rate of any developed country.

About ReShape Lifesciences Inc

ReShape Lifesciences™ (OTCQB: RSLS) is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Investor Contact:Scott YoungstromChief Financial OfficerReShape Lifesciences Inc.+1-949-429-6680 x106[email protected][1]

SOURCE: ReShape Lifesciences Inc.

Topic: Press release summarySectors: BioTech, HealthCare[2][3] http://www.acnnewswire.com From the Asia Corporate News Network

Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

References

  1. ^ [email protected] (www.acnnewswire.com)
  2. ^ BioTech (www.acnnewswire.com)
  3. ^ HealthCare (www.acnnewswire.com)

Read more http://www.acnnewswire.com/press-release/english/51238/

Popular

Cybersecurity training in the era of remote work

Before the pandemic, IT managers had the comfort of knowing employees were working in the office within a secured network. This gave organisations the security of company documents being saved on internal systems, collaboratio...

Customer Acquisition and Loyalty Top Small Retail’s Priority List Amid Economic Headwinds

While some small and medium-sized Australian  retailers are surpassing performance expectations in the face of significant challenge, many say  they are failing to meet their financial benchmarks, the inaugural ARA & Ameri...

Icon Agency hires Senior Account Director to lead new Sydney office

Niall Hughes will lead Icon’s new Sydney office, adding experience in both Australian and UK markets. Icon Agency welcomes Niall Hughes as Senior Account Director Sydney, bringing a wealth of PR experience from across industr...

Virtual Office
Tomorrow Business Growth